What is the appropriate starting dose of citalopram for an adolescent (aged 12‑17)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Citalopram Starting Dose for Adolescents

The recommended starting dose of citalopram for adolescents (aged 12-17) is 10 mg once daily 1.

Dosing Algorithm

Initial Dosing

  • Start at 10 mg once daily (morning or evening, with or without food)
  • This lower starting dose is critical for adolescents, as starting at higher doses increases the risk of deliberate self-harm and suicide-related events 1

Dose Titration

  • Increase by 10 mg increments at intervals of no less than one week if clinically indicated 1
  • Target effective dose: 20 mg/day 1
  • Maximum dose: 60 mg/day (though note important caveats below) 1

Critical Safety Considerations

Important Caveats About Maximum Dosing

While the GLAD-PC adolescent depression guidelines list a maximum of 60 mg/day 1, the FDA drug label for adults recommends a maximum of 40 mg/day due to QT prolongation risk 2. Given that adolescents generally require lower effective doses than adults 1, and considering the cardiac safety concerns, prudent practice would limit adolescent dosing to 40 mg/day maximum.

FDA Approval Status

  • Citalopram is NOT FDA-approved for pediatric depression 1
  • Only fluoxetine (all ages) and escitalopram (≥12 years) have FDA approval for adolescent depression 1
  • Despite lack of approval, citalopram is commonly used off-label in this population

Black Box Warning Monitoring

  • Close monitoring is mandatory, especially during the first few months and after dose changes 1
  • Monitor for clinical worsening, suicidality, and unusual behavioral changes
  • Contact (in-person or telephone) should occur shortly after treatment initiation 1

Evidence Supporting This Dosing

The primary evidence comes from the 2018 GLAD-PC guidelines 1, which represent the most authoritative source for adolescent depression management in primary care. These guidelines explicitly state that effective dosages for antidepressants in adolescents are lower than adult guidelines 1.

Research data supports this approach: A randomized controlled trial in children and adolescents used an initial dose of 20 mg/day with option to increase to 40 mg/day at week 4, achieving a mean dose of approximately 24 mg/day 3. However, starting at 10 mg allows for better tolerability assessment and aligns with the safety principle of avoiding higher starting doses 1.

Common Pitfalls to Avoid

  1. Do not start at 20 mg (the adult starting dose) - this increases suicide risk 1
  2. Do not use adult dosing guidelines - adolescents require lower doses 1
  3. Do not skip the monitoring plan - regular follow-up is essential for safety 1
  4. Do not abruptly discontinue - taper gradually to avoid withdrawal effects 1

Additional Monitoring Requirements

  • Inform patient and family about possible adverse effects including behavioral activation, switch to mania, and suicide-related events 1
  • Monitor weight and growth regularly in adolescents, as SSRIs can cause decreased appetite and weight loss 2
  • Ensure contraindications are checked (MAOIs) 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.